E
Erin Bliven-Sizemore
Researcher at Centers for Disease Control and Prevention
Publications - 15
Citations - 1195
Erin Bliven-Sizemore is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Rifapentine & Tuberculosis. The author has an hindex of 8, co-authored 15 publications receiving 1028 citations.
Papers
More filters
Journal ArticleDOI
Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Timothy R. Sterling,M. Elsa Villarino,Andrey S. Borisov,Nong Shang,Fred M. Gordin,Erin Bliven-Sizemore,Judith Hackman,Carol Dukes Hamilton,Dick Menzies,Amy Kerrigan,Stephen E. Weis,Marc H Weiner,Diane Wing,Marcus Barreto Conde,Lorna Bozeman,C. Robert Horsburgh,Richard E. Chaisson +16 more
TL;DR: The use of rifapentine plus isoniazid for 3 months was as effective as 9 months of isoniaZid alone in preventing tuberculosis and had a higher treatment-completion rate.
Journal ArticleDOI
Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations
Marc H Weiner,Charles A. Peloquin,William J. Burman,Chi Cheng Luo,Melissa Engle,Thomas J. Prihoda,William R. Mac Kenzie,Erin Bliven-Sizemore,John L. Johnson,Andrew Vernon +9 more
TL;DR: Evaluated rifampin pharmacokinetics in relation to tuberculosis, geographic region, race, and single nucleotide polymorphisms of the human transporter genes SLCO1B1, SLCo1B3, and MDR1 suggested that additional absorption or metabolic processes affect rifampsin exposure with tuberculosis disease.
Journal ArticleDOI
Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.
Kelly E. Dooley,Erin Bliven-Sizemore,Michael Weiner,Yanhui Lu,Eric L. Nuermberger,W C Hubbard,E J Fuchs,M T Melia,W J Burman,Susan E. Dorman +9 more
TL;DR: Daily doses as high as a prespecified maximum of 20 mg/kg/day of RPT were well tolerated, its PK were less than dose‐proportional, and its CYP3A induction was robust.
Journal ArticleDOI
Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap
Payam Nahid,Jussi J. Saukkonen,William R. Mac Kenzie,John L. Johnson,Patrick P. J. Phillips,Janet Andersen,Erin Bliven-Sizemore,John T. Belisle,W. Henry Boom,Annie Luetkemeyer,Thomas B. Campbell,Kathleen D. Eisenach,Richard Hafner,Jeffrey L. Lennox,Mamodikoe Makhene,Susan Swindells,M. Elsa Villarino,Marc H Weiner,Constance A. Benson,William J. Burman +19 more
TL;DR: Recommendations for the qualification and validation of biomarkers of treatment outcome, the standardization of specimen and data collection for future clinical trials, and the creation of a specimen repository to support biomarker testing are summarized.
Journal ArticleDOI
Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.
Payam Nahid,Erin Bliven-Sizemore,Leah G. Jarlsberg,Mary Ann De Groote,John L. Johnson,Grace Muzanyi,Melissa Engle,Marc H Weiner,Nebojsa Janjic,David Sterling,Urs A. Ochsner +10 more
TL;DR: Serum proteins involved in the coagulation cascade, neutrophil activity, immunity, inflammation, and tissue remodeling were found to be associated with TB treatment response.